Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Glioma × LY-2157299 × Clear all

Phase

Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Pancreatic Neoplasms 2 Neoplasms 2 Neoplasm Metastasis 1 Glioma 1 Carcinosarcoma 1 Carcinoma, Hepatocellular 1

Interventions

Temozolomide 39 Radiotherapy 13 Magnetic Resonance Spectroscopy 9 Bevacizumab 8 Surgical Procedures, Operative 7 Irinotecan 7 Radiation 6 Carboplatin 6 ribociclib 5 Specimen Handling 5 Radiosurgery 5 Nivolumab 5 Imiquimod 5 Flucytosine 5 Filgrastim 5 Erlotinib Hydrochloride 5 Carmustine 5 Aminolevulinic Acid 5 vandetanib 4 sargramostim 4 Topotecan 4 O(6)-benzylguanine 4 Imatinib Mesylate 4 IL13-PE38 4 Etoposide 4 Cyclophosphamide 4 Craniotomy 4 vocimagene amiretrorepvec 3 lentiviral minigene vaccine of COVID-19 coronavirus 3 Thiotepa 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01682187 2024-11-07

A Dose-Escalation Study in Participants With Recurrent Malignant Glioma

Eli Lilly and Company

Phase 1 Completed

Glioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡